

260
204

Señor

SUPERINTENDENTE DELEGADO PARA LA PROPIEDAD INDUSTRIAL
DIVISION DE NUEVAS CREACIONES

E. _____ S. _____ D. _____

Re: P1.-40 J'S, LLC.-Expediente número 00-097.103.-

1. Me refiero al asunto de la referencia.
2. Por medio del presente, atentamente me permito manifestar que hubo un cambio de apoderado para todos los asuntos de la Propiedad Industrial en Bogotá de la sociedad **40 J'S, LLC.**
3. En consecuencia, atentamente solicito a ese Despacho reconocirme personería en este asunto, de conformidad con la sustitución de poder adjunta, otorgada a favor de la SUSCRITA.
4. Por lo tanto, ruego a usted notificarme de las providencias expedidas dentro de este expediente y notificadas al anterior apoderado, que actualmente se encuentran pendientes de cumplimiento o de respuesta.
5. Solicito a ese Despacho proceder de conformidad.

Atentamente,


ALICIA LLOREDA RICAURTE

T.P. 53.215

Código 231

Señor
SUPERINTENDENTE DE INDUSTRIA Y COMERCIO
DIVISION DE NUEVAS CREACIONES
E. S. D.

Ref: P1.-40 J'S, LLC.-Expediente No. 00-097.103.-

Yo, **JOSE ANTONIO LLOREDA**, mayor de edad y vecino de esta ciudad, abogado titulado e inscrito, identificado como aparece al pie de mi firma, actuando en mi carácter de Representante Legal en Bogotá para asuntos relacionados con la propiedad industrial de **40 J'S, LLC.**, sociedad organizada y existente de conformidad con las leyes del Estado de Kentucky, Estados Unidos de América, domiciliada en Ft. Thomas Estado de Kentucky, Estados Unidos de América, tal y como consta en este expediente, atentamente manifiesto a usted que **SUSTITUYO** el poder a mi conferido a la doctora **ALICIA LLOREDA RICAURTE**, abogada titulada e inscrita, identificada con la cédula de ciudadanía No. 39.690.713 de Usaquén y Tarjeta Profesional No. 53.215, para que continúe representando a la mencionada sociedad en el expediente de la referencia.

El mencionado apoderado tendrá las mismas facultades a mi conferidas, en especial, renunciar, recibir, sustituir, desistir, presentar recursos, conciliar, transigir, y en fin, para todo lo que se encamine a la correcta defensa de los intereses de la sociedad en cuyo nombre habito.

Ateptamente

NOTARIA SEXTA DE BOGOTA

RECONOCIMIENTO Y PRESENTACION PERSONAL

Bogotá, D.C.

Ante mi PABLO MENDEZ BARAJAS

NOTARIO SEXTO(E) DEL CIRCULO DE

BOGOTA

Comparecieron: Jose Antonio Lloreda

quien (os) exhibió(non) la(s) C.C.
17.159.681
T.P. 10784

y Declara que es el mismo/a

C. T. N.

se firmó en esta Agencia y se imprimió

JOSE ANTONIO LLORED
C.C. No. 17.159.681 de Bogotá

206 *zpc*

DIVISION DE NUEVAS CREACIONES

RADICACIÓN EXPEDIENTE No. 00-97103

**EL EXTRACTO DE LA PRESENTE SOLICITUD DE PATENTE DE INVENCION
FUE PUBLICADO EN LA GACETA DE PROPIEDAD INDUSTRIAL No 525, DE
FECHA 28 DE FEBRERO DE 2003, EL TERMINO HABIL SEÑALADO POR LA
LEY EXPIRA EL 29 DE MAYO DE 2003.**

NOTA: Dentro del plazo de los seis (6) meses siguientes a partir de la fecha de publicación en la gaceta de Propiedad Industrial, deberá solicitar y cancelar el examen de patentabilidad so pena de que la solicitud caiga en abandono, de acuerdo con lo establecido en el Artículo 44 de la Decisión 486/2000.

SE PRESENTARON OPOSICIONES POR PARTE DE TERCEROS.

SI _____

NO X _____

**Carrera 13 No. 27-00 Piso 5 y 10
Consultador: 534 12 21-2-3-4
Fax: 281 31 25 e-mail: info@sic.gov.co
Santa Fe de Bogotá D.C. - Colombia**

zpc

763
207

**SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIVISIÓN DE NUEVAS CREACIONES**

2020/
Bogotá, D.C.,

Doctora
Alicia Lloreda Ricaurte
Apoderada

Oficio N° 06688

REFERENCIA	Radicación	00 97103
	Trámite	002
	Evento	001
	Actuación	430
	Folios	012

Como resultado del examen de patentabilidad de la solicitud de patente de invención N° 00 97103, realizado según el artículo 45 de la decisión 486 de la comisión de la Comunidad Andina, se notifica:

Documentos estudiados:

- . Descripción: folios 5-21
- . Ejemplos:
- . Capítulo reivindicatorio estudiado: folios 22-25
- . Se reivindica prioridad presentada en Estados Unidos, el 22.12.99, bajo el número 09/489959

Objeto de la invención

Según las reivindicaciones 1 a 31 de la presente solicitud, se refiere a un aplicador que se puede manejar manualmente para la estimulación del área sensible de los labios y del clítoris de una mujer que comprende un reservorio, un compuestos estimulante y un aplicador.

Clasificación internacional de patentes A 61 K 31/045

Análisis de la Unidad de Invención

El art. 25 de la decisión 486 contempla que *"La solicitud de patente sólo podrá comprender una invención o un grupo de invenciones relacionadas entre sí, de manera que conformen un único concepto inventivo"*

208

Teniendo en cuenta lo anterior, la presente solicitud propone dos invenciones diferentes, a saber:

- Reivindicaciones 1-14: un aplicador de manejo manual para la aplicación de un estimulante.
- Reivindicaciones 21-27: una preparación que contiene L-arginina y mentol

En consecuencia, el presente requerimiento se hace sobre las reivindicaciones 21-27.

Excepciones a la patentabilidad

El artículo 20d de la decisión 486 establece que *"No serán patentables los métodos terapéuticos o quirúrgicos para el tratamiento humano o animal, así como los métodos de diagnóstico aplicados a los seres humanos o a animales"*

Teniendo en cuenta lo anterior, el contenido de las reivindicaciones 15-20 y 28-31 que tratan de "Un método para sensibilizar el tejido...", no es patentable.

Claridad de la solicitud

El art. 30 de la Decisión 486 contempla que *"Las reivindicaciones definirán la materia que se desea proteger mediante la patente. Deben ser claras y concisas y estar enteramente sustentadas por la descripción."*

El término "epitelio no queratinizado" de las reivindicaciones 21-27 no es claro, ya que no permite a la persona versada en la materia a determinar la parte o partes del cuerpo en donde va a ser aplicada la composición, debido a que hay mucho tejido no queratinizado en el cuerpo humano y puede interpretarse que las composiciones también se pueden aplicar en pulmones, esófago, vejiga que son no queratinizados. Se recomienda reemplazar por el área específica del cuerpo donde va a ser aplicada la composición.

El término "labios" es vago, debido a que no se especifica si es en la zona genital o en la boca, haciendo poco clara la reivindicación 21

Favor hacer las aclaraciones y correcciones del caso.

Determinación del estado de la técnica:

Consultadas las fuentes de información con que cuenta este despacho, se encontraron los siguientes documentos, anteriores a la fecha de prioridad de la presente solicitud - 22.12.99-, relacionados con la materia de la presente solicitud:

N°	Documento	Título	Fecha de publicación
1	WO 9913717	"Un vehículo de arginina que causa efectos beneficiosos"	25.03.99

245
209

Evaluación de los requisitos de patentabilidad:

El artículo 14 de la decisión 486 de la comisión de la comunidad andina establece que:
"Los países miembros otorgarán patentes para las invenciones, sean de producto o de procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial"

En cumplimiento del artículo 14 de la decisión 486 de la comisión de la comunidad andina, se procedió a evaluar los requisitos de novedad, nivel inventivo y aplicación industrial con el fin de establecer la patentabilidad de la invención reivindicada en la solicitud en estudio.

Evaluación del NIVEL INVENTIVO

El artículo 18 de la decisión 486 dispone *"Se considerará que una invención tiene nivel inventivo, si para una persona del oficio normalmente versada en la materia técnica correspondiente, esa invención no hubiese resultado obvia ni se hubiese derivado de manera evidente del estado de la técnica"*

La publicación WO 9913717 se relaciona con composiciones tópicas que contienen L-arginina que tienen efectos como el calentamiento de tejidos fríos o la cura de la impotencia a través de la restauración de los mecanismos naturales que se basan en la mejora de la entrega de sangre en los tejidos.

Teniendo en cuenta el objeto de la presente solicitud, el cual es proveer una composición para el tratamiento de la impotencia femenina mediante la aplicación tópica de L-arginina es obvio que una persona versada en la materia utilice las enseñanzas del documento citado y haga una composición oleosa alternativa con mentol, del cual es conocido su efecto rubefaciente (tal como se dice en la descripción), para llegar a la composición que se pretende proteger

Además no se demuestra que las composiciones de la presente solicitud presentan efectos superiores o inesperados a las reportadas en el estado de la técnica, es decir que se presente un efecto sinérgico entre el mentol y la L-arginina comprobado que evidencien un efecto mejorado o sorprendente de la composición que se reivindica.

Lo anterior puede afectar en nivel inventivo de la presente solicitud.

En conclusión los requisitos de patentabilidad de la presente solicitud se encuentran afectados así:


Nº	Documento	Reivindicaciones afectadas	Requisito que afecta
1	WO 9913717	21-27	Nivel Inventivo

En cumplimiento del artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina, se le indica que debe dar respuesta dentro del término de sesenta días contados a partir de la fecha de la notificación de la presente comunicación. En caso de no dar

746
240

respuesta al presente requerimiento, o si a pesar de la respuesta subsistieran los impedimentos para la concesión, se denegará la patente.

Notifíquese el presente oficio conforme a lo dispuesto en el numeral 5.2, literal e), del capítulo 5 del título primero de la Circular Única N° 10 de 2001


Álix Carmenza Céspedes de Vergel
Jefe de la División de Nuevas Creaciones

El anterior requerimiento fue notificado por fijación en lista, de fecha 22 JUN. 2006

CONCEPTO TÉCNICO Número 0946	EXAMINADOR TÉCNICO Código 202024
--	--

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A01N 37/20	A1	(11) International Publication Number: WO 99/13717 (43) International Publication Date: 25 March 1999 (25.03.99)
(21) International Application Number: PCT/US98/19429 (22) International Filing Date: 17 September 1998 (17.09.98) (30) Priority Data: 08/932,227 17 September 1997 (17.09.97) US 08/932,595 17 September 1997 (17.09.97) US 08/936,188 17 September 1997 (17.09.97) US 08/936,189 17 September 1997 (17.09.97) US (71) Applicant: STRATEGIC SCIENCE & TECHNOLOGIES, INC. (US/US); P.O. Box 392, Newton, MA 02159 (US). (72) Inventor: FOSSEL, Eric; 17 Sunset View Road, South Hero, VT 05486 (US). (74) Agent: LORUSSO, Anthony, M.; Lorusso & Loud, 440 Commercial Street, Boston, MA 02190 (US).	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: A DELIVERY OF ARGININE TO CAUSE BENEFICIAL EFFECTS (57) Abstract A delivery vehicle and method for delivering, either topically or orally, a nitric oxide releasing substance such as L-arginine 31 into human or mammalian tissue for the purpose of producing beneficial effects such as the relief of pain, the warming of cold tissues, the growth of hair on the scalp, the healing of leg ulcers, the relief of impotence as well as other beneficial effects. The delivery vehicle provides a hostile biophysical environment which facilitates and promotes the migration of the nitric oxide releasing substance into the tissue.		

218
212

A Delivery of Arginine to Cause Beneficial Effects

Background of the Invention

Field of the Invention

This invention relates, in general, to a delivery vehicle, either topical or oral, which contains substances including, but not limited to, arginine and L-arginine. The purpose of this delivery vehicle is to introduce arginine or L-arginine into human or mammalian tissue for the purpose of producing beneficial effects such as the relief of pain, the warming of cold or cool tissues, the growth of hair on the scalp, the healing of leg ulcers which are often secondary to diabetes or confinement to bed, the relief of impotence, as well as beneficial effects through the restoration of natural mechanisms based on improvement of local blood supply.

Prior Art

Approaches to improving local blood flow have been many and consist of both systemic and topical approaches. Many beneficial effects could be obtained should improvement in local blood flow be achieved since impairment of local blood flow causes a variety of negative consequences. Among these are cold hands and feet, certain forms of impotence, baldness, and leg ulcers.

The fundamental basis for cold tissue of the hands, fingers, feet and toes as well as other cold tissue is insufficient blood flow to the tissue. It has been suggested by some that increasing blood flow through relaxation of blood vessels, particularly small and very small vessels will warm cold tissue. However, many attempts to warm by use of agents which produce vasodilation and therefore increased blood flow have produced negative results.

Previously cold hands or feet have been treated by wearing warm socks or gloves, sometimes even socks or gloves which are mechanically heated. The use of hot packs and glove or shoe inserts which generate heat through chemical reactions have also been potential solutions. Another method of

213

treatment is the application of certain liniments which are irritants. These liniments include the red pepper derived substance, capsaicum, and its source extract oleoresin capsicum. More recently, topical creams containing nitroglycerin have been used. However, nitroglycerin is a cardioactive drug, and thus its use raises concerns about its effect on the heart. Although all of these approaches may work at one level or another, they are often extremely transient in nature.

Furthermore, it has long been recognized that impaired blood flow to the penis is a major cause of erectile failure (impotence) in men. It has been discovered via *in vitro* tissue culture experiments and various animal experiments that nitric oxide is an important mediator of relaxation of the vessels in penile cavernous tissue. Topical nitroglycerin has been used in the treatment of impotence because of its ability to dilate vessels. However, the results of such treatments have been inconclusive and the treatment has proven to be not well tolerated because of the cardiac response to nitroglycerin.

It has also been recognized that deficiencies in blood flow in the scalp occur in male pattern baldness. Topical minoxidil has been used as an agent for hair growth in male pattern baldness with varying results. The suggestion has been made that minoxidil operates by increasing in the blood supply to the scalp.

Furthermore, there have been many approaches to overcoming pain in the prior art. These attempts consist mostly of oral analgesic agents ranging from aspirin and ibuprofen to more powerful narcotic oral agents such as codeine. Alternatively, in cases where a subject suffers from severe pain, narcotic agents including morphine have been used. It has been found that the amino acid L-arginine is a precursor to the natural endogenous analgesic substance, kyotorphin. It has been shown that intravenous administration of large amounts (30 g/patient) of L-arginine is successful in overcoming pain. It is thought that this treatment exerts its effect by increasing levels of kyotorphin. However, this treatment is impractical for use in everyday life and is reserved only for the most extreme forms of chronic pain. Others have found that nitric oxide, whose biochemical precursor is L-arginine, potentiates b-endorphin-

210

214

induced pain relief. Another form of pain relief, which is distinct from the use of arginine, is the application of capsaicin, a substance derived from hot peppers.

SUMMARY OF THE INVENTION

In accordance with the present invention, it has been discovered that the delivery of the nitric oxide precursor, arginine and its derivatives, by either a topical approach, an oral approach or a combination of both, produce a variety of beneficial effects due to the increased blood flow caused by the subsequent release of nitric oxide into the blood. These beneficial effects include the warming of cool or cold tissue, penile erection, restored hair growth and the healing of leg ulcers. Also, according to the present invention, the topical delivery of arginine, when fortified with capsaicin, capsaicum or its source extract, oleoresin capsicum, can alleviate pain when administered to a specific area of the body.

In one important embodiment of the present invention, when a delivery vehicle containing arginine or arginine derivatives in a concentration sufficient to produce the desired effects, along with sodium chloride or other salts at a concentration sufficient to produce a hostile biophysical environment, in either a topical form, oral form or a method combining both the oral form and the topical form is applied to a selected area of cool or cold tissue, the tissue is subsequently warmed. The warming of the tissue is caused by the increase in blood flow to the treated area. This warming effect can be prolonged, often lasting from 2-18 hours. In persons with very cold tissue (for example 22 ° C) this warming effect can have a magnitude of 10° C or more.

Another embodiment of the present invention is the application of a delivery vehicle containing arginine or arginine derivatives in a concentration sufficient to produce the desired effects, along with sodium chloride or other salts at a concentration sufficient to produce a hostile biophysical environment, in either a topical form, oral form or a method combining both the oral form and the topical form to the penis to increase local blood flow and concurrently overcome impotence.

771
215

membrane. An example of neutralization of charge include the salt, arginine glutamate which is electronically neutral. Other acceptable arginine salts are set forth herein above.

In each case of creating a hostile biophysical environment for the active agent, the agent was added to an appropriate preparation. In the case of creating a high ionic strength ion environment, salts such as but not limited to sodium chloride, potassium chloride, choline chloride, lithium chloride, alone or in combination were added in high concentration to achieve an ionic strength greater than two times the physiological strength of blood. Other highly charged molecules such as polylysine, polyglutamine, polyaspartate or copolymers of such charged amino acids may be used to create the hostile biophysical environment.

Alternatively a hostile biophysical environment may be created by placing the highly charged L-arginine in an hydrophobic, oily environment such as in an oil-based cream containing little or no water. The preferred hydrophobicity or ρ is greater than two times the physiological hydrophobicity of blood. Absorption may further be aided by combining the use of hostile biophysical environments with the use of penetrating agents such as oleoresin capsicum or its constituents or molecules containing heterocyclic rings to which are attached hydrocarbon chains.

If a high or low pH environment is the hostile environment chosen, the preferred pH range is about between 3 to 11 pH.

CLINICAL APPLICATIONS

Example 1

In this example, a person with very cold fingers was provided with the above warming cream consisting of a delivery vehicle of penetrating cream, L-arginine hydrochloride (15% w/v), and sodium chloride (10% w/v). The surface temperature of the subject fingers of the left hand varied from 21 °C to 24 °C . The warming cream was applied by rubbing it into the skin. Surface temperatures of each finger were measured at 15 minute intervals for the initial

7/13
2/6

hour. At the initial 15 minute interval following administration of the warming cream, an identifiable effect had begun to occur with surface temperatures of various fingers rising to 28°C to 29 °C. The maximal effect was reached by 45 minutes with surface temperatures of various fingers becoming 31 °C to 34 °C. The effect was sustained for at least 4 hours.

Example 2

In this example a 53 year old man with baldness consisting of a severely receding hairline as well as a large "bald spot" on the top rear of his head was provided with a penetrating cream containing L-arginine hydrochloride (15% w/v) and sodium chloride (10% w/v). The cream was applied to the bald areas each night before going to bed and was rubbed in extensively for maximal absorption. New hair growth was noted within 2-3 weeks. Within 4 months the receding hairline (previously 4 cm of bald skin) had returned to normal and the "bald spot" previously more than 7 cm in diameter had been reduced to an area of less than 2 cm with even this area showing some new hair growth.

Example 3

In a 54 year old man with a history of impotence administration of 1.5 g L-arginine daily in the form of oral capsules combined with a twice daily administration of a penetrating cream containing L-arginine hydrochloride (15% w/v) and sodium chloride (10% w/v) directly to the penis for 7 days brought initial relief from the symptoms of impotence and allowed the subject to resume normal sexual activity. This relief of symptoms was maintained by continuation of the treatment on a daily basis.

Example 4

In a 52 year old woman with a 13 year history of chronic neck pain, administration of a penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), magnesium chloride (5% w/v) and

2254
217

sodium chloride (5% w/v) every four hours for 1 day followed by twice daily administration directly to the neck brought relief from the pain within the first day. This relief of symptoms was maintained by continuation of the twice daily treatment.

Example 5

In a 35 year old man with a three year history of shoulder pain, application of a penetrating cream containing L-arginine hydrochloride (12.5% w/v) and choline chloride (10% w/v), magnesium chloride (5%), sodium chloride (5%) and oleoresin capsicum (0.5%) every four hours for 1 day followed by twice daily applications directly to the painful area brought relief from pain within 8 hours. The relief of symptoms was maintained by continuation of twice daily treatment regimen.

Example 6

In this example, a 53 year old man with a scalp lacking sufficient hair consisting of a severely receding hairline as well as a large "bald spot" on the top rear of the head was provided with a penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (5% w/v) and magnesium chloride (5% w/v). The cream was applied to the bald areas each night before going to bed and was rubbed in extensively for maximal absorption. New hair growth was noted within 2-3 weeks. Within 4 months, the receding hairline (previously 4 cm of bald skin) had returned to normal and the "bald spot," previously more than 7 cm in diameter had been reduced to an area of less than 2 cm with some new hair growth in the 2 cm area.

Example 7

In a 54 year old man with a history of impotence, twice daily administration of a penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (10% w/v) and magnesium chloride (5%

265
218

w/v) directly to the penis twice daily for 7 days brought initial relief from the symptoms of impotence and allowed the subject to resume normal sexual activity. This relief of symptoms was maintained by continuation of the treatment daily.

Example 8

In a 62 year old man with a history of impotence, placement of a condom containing a water based penetrating cream containing L-arginine hydrochloride (12.5% w/v), choline chloride (10% w/v), sodium chloride (5% w/v) and magnesium chloride (5% w/v) on the man's flaccid penis for 30-60 minutes before erection was desired resulted in the formation of an erection when sexual performance was needed. The erection was easily obtained and normal sexual activity was conducted.

Example 9

In this example, a person (female, age 52) with very cold fingers was provided with the above warming cream consisting of a delivery vehicle of penetrating cream, L-arginine hydrochloride (12.5%), choline chloride (10%), magnesium chloride (5%) and sodium chloride (5%). The surface temperature of the subject fingers of the left hand varied from 21 to 24 C°. The warming cream was applied by rubbing it into the skin. Surface temperatures of each finger were measured at 15 minute intervals for the initial hour. At the initial 15 minute interval following administration of the warming cream, a noticeable effect had begun to occur with the surface temperatures of various fingers rising to between 26 to 29 C°. Maximal effect was reached by 45 minutes with surface temperatures of various fingers reaching 31 to 34 C°. The effect was sustained for at least 4 hours.

As illustrated by the examples, it can accordingly be seen that the present invention provides a method for administering a nitric oxide releasing substance in a delivery vehicle which when applied to cold, and often painful tissue, causes an increase in skin temperature through utilization of one of

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

219

RADICACIÓN: 0-97103

EDICTO No. 17305

**LA SECRETARÍA GENERAL AD-HOC
HACE SABER:**

Que esta Superintendencia profirió Resolución No. 28174 de 28-OCT-2006. Que el contenido de la parte resolutive es como sigue: El Superintendente de Industria y Comercio.

RESUELVE

ARTICULO PRIMERO: Negar el privilegio de patente de invención para la solicitud correspondiente a "COMPUESTOS PARA SESIBILIZACION DE TEJIDOS PARA MUJERES, CON METODOS Y APARATO PARA LA LIBERACION DE ESTOS COMPUESTOS".

ARTICULO SEGUNDO: Notificar personalmente el contenido de la presente resolución a la doctora Alicia Llorada Ricaurte, en su calidad de representante legal de 40 JS, Llc., entregándole copia de la misma, advirtiéndole que contra ella procede el recurso de reposición interpuesto ante el Superintendente de Industria y Comercio, al momento de la notificación o dentro de los 5 días hábiles siguientes a ella.

NOTIFIQUESE Y CUMPLASE

Dada en Bogotá, D.C., a los **26 OCT. 2006**

EL SUPERINTENDENTE DE INDUSTRIA Y COMERCIO,


JAIME ROBERTO ESCOBAR

Para notificar a los interesados, se fija el presente EDICTO en lugar visible al público en la SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO, por el término de (10) diez días hábiles contados a partir de las 8:30 a.m. de hoy.

Secretaría General Ad-Hoc 09-NOV-2006 Este edicto se desliza hoy 23-NOV-2006 a las cinco (5:00 p.m.)
Secretaría General Ad-Hoc
EDICTO No. 17305